4.3 Sympatomimetic drugs Flashcards
CATECHOLAMINE BIOSYNTHESIS
____________ is converted into ___________ by ______________ (rate-limiting step):
- L-DOPA is then converted by the _________________ into dopamine (within the cytoplasm) → packaged into vesicles along with __________________ –> Dopamine is converted into noradrenaline by dopamine β-hydroxylase (end product in some regions of the sympathetic system)
- Noradrenaline is further metabolised into adrenaline by ____________ in other regions
L-tyrosine; L-DOPA; tyrosine hydroxylase;
DOPA decarboxylase enzyme;
dopamine β-hydroxylase;
phenylethanolamine N-methyltransferase
The organs and tissues which respond to either noradrenaline or adrenaline contain 4 main types of adrenoceptors (α1, α2, β1, β2):
- All the adrenoceptors are G-protein coupled receptors; α1 signals through ________________, while α2, β1, β2 signal through ________________
Noradrenaline and adrenaline are endogenous mediators which are non-selective (with slight differences in potency):
- Adrenaline is ______________, while noradrenaline is ________________
- Potencies are the same between the two α and two β receptors
PLC, IP3 and DAG;
cAMP (α2 reduces, β1, β2 increases);
less potent on the α receptors than β receptors;
more potent on the α receptors than β receptors
Adrenoceptors are differentially distributed throughout the body, which determines the effects of the endogenous mediators and sympathomimetics:
- Activation of the sympathetic nervous system allows the body to cope with stress (fright, fight or flight response)
- Blood vessels with α1 adrenoceptors tend to be ___________, while blood vessels with β2 adrenoceptors tend to be __________________
o Constricted blood vessels tend to supply areas of less importance → shunts blood to dilated blood vessels to skeletal muscles (important in stress)
- Main location of α2 adrenoceptors (presynaptic autoinhibitory receptors) are on __________________
constricted;
dilated in a sympathetic response;
presynaptic terminals of noradrenergic neurones → limits further NA release
Uptake 1
- Back into presynaptic terminal
- Metabolised by _____________ into inactive metabolites
monoamine oxidase (MAO)
Uptake 2
- Into postsynaptic cell
- Degraded by ______________ into inactive metabolites
catechol-O-methyltransferase (COMT)
what is the selectivity of adrenaline?
α1 = α2 = β1 = β2
what is the selectivity of phenylephrine?
α1 > α2 > β1 / β2
whit is the selectivity of clonidine?
α2 > α1 > β1 / β2
what is the selectivity of isoprenaline?
β1 / β2 > α1 / α2
What is the selectivity of dobutamine?
β1 > β2 > α1 / α2
what is the selectivity of salbutamol?
β2 > β1 > α1 / α2
Adrenaline is released naturally from the ___________________, and is also used as a drug in medical emergencies → non-selective agonist (activates all adrenoceptors):
- Administered______________ → poor oral absorption (charged molecule which has difficulty passing through membranes) - Rapidly metabolised in the gut, liver, and other tissues by _____________ –> Short-lived duration of action (within minutes)
adrenal medulla by chromaffin cells;
IV/IM/locally/topically;
MAO and COMT
ADRENALINE: Allergic reactions/ anaphylaxis (IgE reactions): Histamine from mast cells acts on blood vessels to cause ________________ → hypotensive crisis; bronchoconstriction → breathing difficulties
Adrenaline (given IM as autoinjector delivery) counteracts via:
- ______________ (α1) → increase BP
- _____________ (β1) → increase CO and BP
- ______________ (β2) → open the airways
- Blocks release of hypotensive and bronchoconstrictor mediators from mast cells and other WBCs
massive peripheral vasodilation ;
Peripheral vasoconstriction;
Increase HR and contractility;
Bronchodilation
ADRENALINE: Acute management of cardiogenic shock:
- Heart fails to pump enough O2 rich blood to the body (decreased CO) leading to severe MI and cardiac arrest
- Adrenaline counteracts via ______________
positive inotropic & chronotropic actions
ADRENALINE: Prolonged duration of LA
Adrenaline has ______________ → prolongs drug action and minimises dose of LA required
α1 vasoconstrictor properties